Alexza Pharmaceuticals News

"We are disappointed we received a complete response letter from the FDA for our ADASUVE NDA.

As large pharmaceuticals face major patent expirations in 2012 they have looked to biotech companies to provide new streams of revenue.

Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for ADASUVEa inhalation powder, 5 mg and 10 mg.A The CRL was issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the ... (more)

We screened for issues that were showing unusual volatility or volume patterns, often caused by imminent earnings releases, regulatory decisions, or other material corporate developments.

Alexza Pharmaceuticals, Inc. - Financial and Strategic SWOT Analysis Review Summary Alexza Pharmaceuticals, Inc.